Get the Stockscreener App
1.98
5.71%
-0.12
After Hours:
1.97
-0.01
-0.51%
Tuhura Biosciences Inc stock is traded at $1.98, with a volume of 102.09K.
It is down -5.71% in the last 24 hours and down -56.77% over the past month.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
See More
Previous Close:
$2.10
Open:
$2.12
24h Volume:
102.09K
Relative Volume:
0.44
Market Cap:
$83.80M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-2.94%
1M Performance:
-56.77%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.92
$2.12
1-Week Range:
$1.80
$2.29
52-Week Range:
$1.80
$7.20
Tuhura Biosciences Inc Stock (HURA) Company Profile
Name
Tuhura Biosciences Inc
Sector
Industry
Phone
813-875-6600
Address
10500 UNIVERSITY CENTER DR., TAMPA
Compare HURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
1.98 | 83.80M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-25 | Initiated | H.C. Wainwright | Buy |
| Dec-19-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-05-24 | Initiated | Maxim Group | Buy |
Tuhura Biosciences Inc Stock (HURA) Latest News
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
TuHURA Biosciences Expands Board with New Appointment - TipRanks
TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors - Joplin Globe
TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference - Weatherford Democrat
What is HC Wainwright’s Estimate for HURA Q2 Earnings? - Defense World
KINETA, INC./DE SEC 10-K Report - TradingView
TuHURA Biosciences (NASDAQ:HURA) Now Covered by Analysts at HC Wainwright - Defense World
HC Wainwright Initiates TuHURA Biosciences at Buy With $13 Price Target -March 03, 2025 at 07:29 am EST - Marketscreener.com
TuHURA Biosciences (HURA) to Release Earnings on Wednesday - Defense World
TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - Milton Daily Standard
Apollon Wealth Management LLC Invests $253,000 in TuHURA Biosciences (NASDAQ:HURA) - MarketBeat
TuHURA Biosciences: A Hold On Only The Faintest Glimmers Of Efficacy (NASDAQ:HURA) - Seeking Alpha
TuHURA Biosciences secures $3M through warrant exercises By Investing.com - Investing.com Australia
TuHURA Biosciences secures $3M through warrant exercises - Investing.com India
Kineta sells Genentech and Merck deals to investor ahead of TuHURA merger - Fierce Biotech
Equities Analysts Offer Predictions for HURA Q2 Earnings - MarketBeat
TuHURA Biosciences (HURA) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Research Analysts Issue Forecasts for HURA Q2 Earnings - Defense World
TuHURA Biosciences’ Acquisition of Kineta - Global Legal Chronicle
HURA: Initiating an Immune Response - Yahoo Finance
TuHURA Biosciences (NASDAQ:HURA) Trading Down 2.6%Here's Why - MarketBeat
TuHURA Biosciences (NASDAQ:HURA) Trading Down 2.6% – Here’s What Happened - Defense World
TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - ACCESS Newswire
When Will TuHURA Biosciences, Inc. (NASDAQ:HURA) Turn A Profit? - Simply Wall St
When Can We Expect A Profit From TuHURA Biosciences, Inc. (NASDAQ:HURA)? - Yahoo Finance
Analyzing Enveric Biosciences (NASDAQ:ENVB) and TuHURA Biosciences (NASDAQ:HURA) - Defense World
Rep. Laurel M. Lee Purchases Shares of TuHURA Biosciences (NASDAQ:HURA) - Defense World
Rep. Laurel M. Lee Buys TuHURA Biosciences (NASDAQ:HURA) Shares - MarketBeat
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of TuHURA Biosciences, Inc.HURA - The Eastern Progress Online
TuHURA Biosciences appoints new accounting firm By Investing.com - Investing.com Australia
TuHURA Biosciences appoints new accounting firm - Investing.com India
TuHURA Biosciences (NASDAQ:HURA) Upgraded to "Strong-Buy" at RODMAN&RENSHAW - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHYF, ML, HURA, KANT on Behalf of Shareholders - Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHYF, ML, HURA, KANT on Behalf of Shareholders - Finansavisen
H.C. Wainwright sets $11 target on HURA with buy rating - Investing.com
Cancer Immunotherapy: TuHURA Biosciences to Acquire Kineta - orrick.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PDCO, ML, HURA, KANT on Behalf of Shareholders - Finansavisen
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ML, PDCO, HURA, KANT on Behalf of Shareholders - GlobeNewswire
Tuhura Biosciences Inc Stock (HURA) Financials Data
There is no financial data for Tuhura Biosciences Inc (HURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):